Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 9/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405964 | 0.82 | EPHB3 (0.39) | EPHB3KDM4EIRAK4STING1 | |
| SCHEMBL405044 | 0.78 | EPHB3 (0.35) | EPHB3IRAK4RIPK2LCK | |
| SCHEMBL405792 | 0.76 | EPHB3 (0.52) | EPHB3KDM4EIRAK4RIPK2LCK | |
| SCHEMBL402097 | 0.70 | JAK2 (0.48) | PDE2AIRAK4STING1JAK2NTRK1 | |
| SCHEMBL24567566 | 0.70 | ACACB (0.42) | KDM4EL3MBTL1SYKRECQLALOX5 | |
| SCHEMBL31678698 | 0.69 | LRRK2 (0.39) | KDM4EIRAK4L3MBTL1JAK2RECQL | |
| SCHEMBL20571301 | 0.68 | POLQ (0.40) | KDM4EL3MBTL1JAK2RECQLALOX5 | |
| SCHEMBL18717545 | 0.67 | PDE2A (0.61) | PDE2AKDM4EIRAK4STING1 | |
| SCHEMBL12708287 | 0.67 | ALOX5 (0.39) | KDM4EIRAK4L3MBTL1JAK2RECQL | |
| SCHEMBL3902859 | 0.64 | ALOX5 (0.45) | KDM4EL3MBTL1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | EPHB3 2273/4885PDE2A 857/4885KDM4E 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.